The proportion of participants with elevated ALT levels at 2 years · relapsing multiple sclerosis
Teriflunomide probably leads to higher the proportion of participants with elevated ALT levels at 2 years compared with placebo (moderate certainty).
1 finding from 1 review
Overall survival · All patients with a diagnosis of multiple myeloma
Bortezomib leads to lower overall Survival compared with no bortezomib (high certainty).
1 finding from 1 review
Health‐related quality of life · All patients with a diagnosis of multiple myeloma
1 finding from 1 review
Thrombocytopenia · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Thrombocytopenia compared with no bortezomib (low certainty).
3 findings from 1 review
OR 2.05 [1.7, 2.48]
8 studies · 3791 participants
Low
OR 1.51 [1.13, 2]
3 studies · 1196 participants
High
OR 2.6 [2.01, 3.35]
5 studies · 2595 participants
Low
Diarrhoea · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Diarrhoea compared with no bortezomib (low certainty).
3 findings from 1 review
OR 2.44 [1.74, 3.43]
8 studies · 3788 participants
Low
OR 6.24 [2.79, 13.98]
4 studies · 1670 participants
Moderate
OR 1.8 [1.22, 2.65]
4 studies · 2118 participants
Moderate
Adverse Events: Peripheral Neuropathy · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to higher adverse Events: Peripheral Neuropathy compared with no bortezomib (moderate certainty).
1 finding from 1 review
Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no… compared with no bortezomib (low certainty).
1 finding from 1 review
Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no… compared with no bortezomib (high certainty).
1 finding from 1 review
Overall Survival ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to lower overall Survival ‐ Bortezomib versus no bortezomib (same background… compared with no bortezomib (moderate certainty).
1 finding from 1 review
Adverse Events: Infections (All) · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to higher adverse Events: Infections (All) compared with no bortezomib (moderate certainty).
1 finding from 1 review
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib showed no clear difference in adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
1 finding from 1 review
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib… compared with no bortezomib (low certainty).
1 finding from 1 review
Adverse effects (cardiac) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Cardiac Disorders compared with no bortezomib (high certainty).
2 findings from 1 review
Adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to higher adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib… compared with no bortezomib (high certainty).
1 finding from 1 review
Overall Survival ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
Bortezomib leads to lower overall Survival ‐ Bortezomib versus no bortezomib (different… compared with no bortezomib (high certainty).
1 finding from 1 review
Progression‐free survival · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to lower progression‐Free Survival compared with no bortezomib (low certainty).
2 findings from 1 review
Odds Ratio 0.67 [0.61, 0.72]
9 studies · 4344 participants
Low
Odds Ratio 0.67 [0.61, 0.75]
4 studies · 2489 participants
Low
Progression‐free survival (PSF) · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to lower progression‐Free Survival ‐ Bortezomib versus no bortezomib (same… compared with no bortezomib (moderate certainty).
1 finding from 1 review
Treatment‐related death · All patients with a diagnosis of multiple myeloma
Bortezomib showed no clear difference in treatment‐related death compared with no bortezomib (low certainty).
1 finding from 1 review
Treatment‐related death ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma
Bortezomib showed no clear difference in treatment‐related death ‐ Bortezomib versus no bortezomib (same… compared with no bortezomib (low certainty).
1 finding from 1 review
Treatment‐related death ‐ Bortezomib versus no bortezomib (different background therapy or other agents) · All patients with a diagnosis of multiple myeloma
It is very uncertain whether bortezomib changes treatment‐related death ‐ Bortezomib versus no bortezomib (different… compared with no bortezomib (very low certainty).
1 finding from 1 review